Literature DB >> 3062384

p21-ras effector domain mutants constructed by "cassette" mutagenesis.

J C Stone1, W C Vass, B M Willumsen, D R Lowy.   

Abstract

A series of mutations encoding single-amino-acid substitutions within the v-rasH effector domain were constructed, and the ability of the mutants to induce focal transformation of NIH 3T3 cells was studied. The mutations, which spanned codons 32 to 40, were made by a "cassette" mutagenesis technique that involved replacing this portion of the v-rasH effector domain with a linker carrying two BspMI sites in opposite orientations. Since BspMI cleaves outside its recognition sequence, BspMI digestion of the plasmid completely removed the linker, creating a double-stranded gap whose missing ras sequences were reconstructed as an oligonucleotide cassette. Based upon the ability of the mutants to induce focal transformation of NIH 3T3 cells, a range of phenotypes from virtually full activity to none (null mutants) was seen. Three classes of codons were present in this segment: one which could not be altered, even conservatively, without a loss of function (codons 32 and 35); one which retained detectable biologic activity with conservative changes but which lost function with more drastic substitutions (codons 36 and 40); and one which retained function even with a nonconservative substitution (codon 39).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062384      PMCID: PMC363598          DOI: 10.1128/mcb.8.8.3565-3569.1988

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  25 in total

1.  Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain.

Authors:  H Adari; D R Lowy; B M Willumsen; C J Der; F McCormick
Journal:  Science       Date:  1988-04-22       Impact factor: 47.728

Review 2.  Oncogenes and cancer: the p21 ras genes.

Authors:  T Y Shih; M O Weeks
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

3.  Mechanism of activation of a human oncogene.

Authors:  C J Tabin; S M Bradley; C I Bargmann; R A Weinberg; A G Papageorge; E M Scolnick; R Dhar; D R Lowy; E H Chang
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

4.  Linker tailing: unphosphorylated linker oligonucleotides for joining DNA termini.

Authors:  R Lathe; M P Kieny; S Skory; J P Lecocq
Journal:  DNA       Date:  1984

5.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

6.  The p21 ras C-terminus is required for transformation and membrane association.

Authors:  B M Willumsen; A Christensen; N L Hubbert; A G Papageorge; D R Lowy
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

7.  Comparative biochemical properties of p21 ras molecules coded for by viral and cellular ras genes.

Authors:  A Papageorge; D Lowy; E M Scolnick
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

8.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

9.  The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity.

Authors:  R W Sweet; S Yokoyama; T Kamata; J R Feramisco; M Rosenberg; M Gross
Journal:  Nature       Date:  1984 Sep 20-26       Impact factor: 49.962

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  17 in total

1.  Phospholipase C(epsilon): a novel Ras effector.

Authors:  G G Kelley; S E Reks; J M Ondrako; A V Smrcka
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

2.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras.

Authors:  D W Stacey; L A Feig; J B Gibbs
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

4.  A ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1.

Authors:  J E DeClue; J C Stone; R A Blanchard; A G Papageorge; P Martin; K Zhang; D R Lowy
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

5.  Genetic definition of ras effector elements.

Authors:  J C Stone; R A Blanchard
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

6.  Transfected human beta-polymerase promoter contains a ras-responsive element.

Authors:  P S Kedar; D R Lowy; S G Widen; S H Wilson
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

7.  Codon cassette mutagenesis: a general method to insert or replace individual codons by using universal mutagenic cassettes.

Authors:  D M Kegler-Ebo; C M Docktor; D DiMaio
Journal:  Nucleic Acids Res       Date:  1994-05-11       Impact factor: 16.971

8.  RAS signalling is abnormal in a c-raf1 MEK1 double mutant.

Authors:  D Bottorff; S Stang; S Agellon; J C Stone
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

Review 9.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

10.  Probing the role of loop 2 in Ras function with unnatural amino acids.

Authors:  H H Chung; D R Benson; V W Cornish; P G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.